Among 117 FLT3 -mutated patients, there was a nonsignificant trend towards improved median OS in quizartinib-treated patients (33 months) versus those who did not receive quizartinib (26 months; HR = 0.688, 95% CI = 0.428–1.106, p = 0.121) [ 108 ].
← all excerpts
Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.
1
—
—